Sarepta Therapeutics, Inc. (SRPT) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 25 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Wed, Aug 5, 2026after close 36 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Wed, Feb 25, 2026after close 56 8-K
Q3 FY2025Mon, Nov 3, 2025after close 34 8-K
Q2 FY2025Wed, Jul 16, 2025after close 16 8-K
Q4 FY2024Wed, Feb 26, 2025after close 57 8-K
Q3 FY2023Mon, Jan 8, 2024during market hours 100 8-K

What they guided beta

Q3 FY2026 "Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments – Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs – Net product revenues for the third quarter 2026 totaled approximately $323.8 million, consisting of approximately $240.3 million of PMO net product revenues and $83.5 million of ELEVIDYS® net product revenue – Continued disciplined financial execution with positive cash flow and GAAP operating loss of ($9.0) million a" exhibit
Q3 FY2026 "DM1 and FSHD programs advancing toward MAD data in fourth quarter of 2026 and preparing for late-stage development: Multiple ascending dose data from SRP-1003 and SRP-1001 are expected in the fourth quarter of 2026, providing important insights including DMPK knockdown and splicing correction in DM1 and DUX4 knockdown in FSHD." exhibit
Q3 FY2026 "The Company expects the PMO franchise to remain strong and is updating its full-year guidance ranges, raising the low end of total net product revenue guidance by $50.0 million to a range of $1.25 billion to $1.3 billion." exhibit
Q3 FY2026 "The Company also narrows its full-year combined non-GAAP R&D and SG&A expenses, lowering the high end of expense guidance by $25.0 million to a range of $800 million to $825 million." exhibit
Q2 FY2026 "ENDEAVOR Cohort 8 expected by year-end 2026 and 12-week data from the full cohort in Q1 2027." exhibit
Q2 FY2026 "Guidance: With six months remaining for the year and consistent with prior expectations toward the lower end of the $1.2-$1.4 billion range, Company narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion while also narrowing combined non-GAAP R&D and SG&A expense guidance from $800.0-$900.0 million to $800.0-$850.0 million." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SRPT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SRPT

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SRPT earnings date badge

HTML

<a href="https://veritasdata.dev/company/SRPT/"><img src="https://veritasdata.dev/embed/SRPT.svg" alt="SRPT earnings date" width="240" height="56"></a>

Markdown

[![SRPT earnings date](https://veritasdata.dev/embed/SRPT.svg)](https://veritasdata.dev/company/SRPT/)

Script

<script async src="https://veritasdata.dev/embed/SRPT.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SRPT"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.